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Abstract
Novel analogs of the P2 receptor antagonist pyridoxal-5′-phosphate-6-phenylazo-2′,4′-
disulfonate (PPADS) were synthesized. Modifications were made through functional group
substitution on the sulfophenyl ring and at the phosphate moiety through the inclusion of
phosphonates, demonstrating that a phosphate linkage is not required for P2 receptor antagonism.
Substituted 6-phenylazo and 6-naphthylazo derivatives were also evaluated. Among the 6-
phenylazo derivatives, 5′-methyl, ethyl, propyl, vinyl, and allyl phosphonates were included. The
compounds were tested as antagonists at turkey erythrocyte and guinea-pig taenia coli P2Y1
receptors, in guinea-pig vas deferens and bladder P2X1 receptors, and in ion flux experiments by
using recombinant rat P2X2 receptors expressed in Xenopus oocytes. Competitive binding assay at
human P2X1 receptors in differentiated HL-60 cell membranes was carried out by using
[35S]ATP-γ-S. A 2′-chloro-5′-sulfo analog of PPADS (C14H12O9N3ClPSNa), a vinyl
phosphonate derivative (C15H12O11N3PS2Na3), and a naphthylazo derivative
(C18H14O12N3PS2Na2), were particularly potent in binding to human P2X1 receptors. The
potencies of phosphate derivatives at P2Y1 receptors were generally similar to PPADS itself,
except for the p-carboxyphenylazo phosphate derivative C15H13O8N3PNa and its m-chloro analog
C15H12O8N3ClPNa, which were selective for P2X vs. P2Y1 receptors. C15H12O8N3ClPNa was
very potent at rat P2X2 receptors with an IC50 value of 0.82 μM. Among the phosphonate
derivatives, [4-formyl-3-hydroxy-2-methyl-6-(2-chloro-5-sulfonylphenylazo)-pyrid-5-
yl]methylphosphonic acid (C14H12-O8N3ClPSNa) showed high potency at P2Y1 receptors with an
IC50 of 7.23 μM. The corresponding 2,5-disulfonylphenyl derivative was nearly inactive at turkey
erythrocyte P2Y1 receptors, whereas at recombinant P2X2 receptors had an IC50 value of 1.1 μM.
An ethyl phosphonate derivative (C15H15O11N3PS2Na3), whereas inactive at turkey erythrocyte
P2Y1 receptors, was particularly potent at recombinant P2X2 receptors.
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INTRODUCTION
Extracellular adenine nucleosides and nucleotides, acting through P1 and P2 receptors
[North and Barnard, 1997; Burnstock, 1996], are widely accepted as neuro-modulators and
neurotransmitters in the central and peripheral nervous systems. Two families of P2
receptors, ligand-gated ion channels (P2X subtype) and G protein-coupled receptors (P2Y
subtype), have been recently classified [Abbracchio and Burnstock, 1994]. Numerous
subtypes of ATP receptors have been cloned, and it is now clear that uracil nucleotides
[Communi and Boeynaems, 1997] are also active or even the preferred ligands at some of
the P2Y subtypes. P2X1–7 and P2Y1,2,4,6 designations have been unambiguously assigned to
mammalian nucleotide receptors [Burnstock and King, 1996; Fredholm et al., 1997],
although there is still uncertainty about the correspondence of these cloned sequences to
pharmacologic phenotypes. Other novel mammalian P2Y subtypes, numbering up to P2Y11,
have recently been reported [Communi et al., 1997].
The most significant evidence for ATP acting as a cotransmitter was reported for the
sympathetic neurotransmission system in which norepinephrine and ATP are coreleased
[Burnstock, 1993]. In vas deferens, isolated blood vessels, skeletal muscle, intestine, kidney
and skin, norepinephrine and ATP cause synergistic constriction by means of α1-
adrenoceptors and P2X receptors, respectively. In rabbit coronary vessels, guinea-pig taenia
coli, rat aorta, and rat mesenteric artery, the predominant effect of those transmitters is
relaxation by means of β-adrenoceptors and P2Y receptors. Besides sympathetic
neurotransmission, P2 receptors are also suggested to function in parasympathetic, sensory-
motor NANC inhibitory, and somatic neuromuscular neurotransmission. In platelets, an as
yet uncloned P2T receptor [Hourani and Hall, 1996; Greco, 1997] has been shown to be
activated mainly by ADP to cause platelet aggregation and is blocked by ATP. More
recently, a hypothesis was reported that P2X3 receptors mediate nociception by means of the
dorsal root ganglia, whereas activation of P1 receptors seems to result in anti-nociception
[Burnstock and Wood, 1996]. The therapeutic potential [Williams, 1996; Williams and
Bhagwat, 1996] and physiologic role of P2 receptors also have been reviewed in various
biological systems, including brain [Inoue et al., 1996], central nervous [Gibb and Halliday,
1996], sensory nervous [Thorne and Housley, 1996], cardiovascular [Rongen et al., 1997],
immune [Di Virgilio et al., 1996], and renal microvascular [Inscho, 1996] systems.
Progress in the field of P2 receptors has been impeded because of the lack of useful ligands,
especially P2 receptor selective antagonists and radioligands [Jacobson et al., 1997]. A
synthetic polyanionic substance, pyridoxal-5′-phosphate-6-phenylazo-2,4-disulfonate
(PPADS), was shown to be a P2 receptor antagonist [Lambrecht et al., 1996]. In smooth
muscle assays, it antagonized P2X receptors in rabbit vas deferens [Lambrecht et al., 1992],
urinary bladder [Ziganshin et al., 1993], isolated blood vessels [Ziganshin et al., 1994],
guinea-pig isolated vas deferens [McLaren et al., 1994], and rat perfused mesenteric arterial
bed [Windscheif et al., 1994]. PPADS was initially reported to show moderate selectivity for
P2X vs. P2Y receptors [Windscheif et al., 1995a]; however, it was later shown to be more
potent than anticipated at P2Y1 receptors [Schachter et al., 1996]. At the P2Y1 subtype,
PPADS was a competitive antagonist exhibiting an equilibrium inhibition constant (Ki)
value of approximately 1 μM. PPADS had low affinity at the adenylate cyclase-coupled
P2Y receptor in rat C6 glioma cells [Boyer et al., 1994], at the P2U receptor in bovine aortic
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endothelial cells [Brown et al., 1995], and at P2T receptors in human platelets [Windscheif et
al., 1995b].
In the present study, the structure-activity relationships (SARs) of a series of pyridoxal-6-
arylazo-5-phosphate derivatives and corresponding phosphonate congeners are reported
(Fig. 1). Both radioligand binding and pharmacologic assays have been conducted with the
aim of developing more potent and selective antagonists for P2 receptor subtypes.
MATERIALS AND METHODS
Pyridoxal-5-phosphate and the reagents for azo coupling reactions were purchased from
Aldrich (St. Louis, MO). The aniline derivatives were obtained from Aldrich, Fluka (St.
Louis, MO), Lancaster (Windham, NH), Pfaltz & Bauer (Waterbury, CT), and Eastman
Kodak (Rochester, NY).
Synthesis
Proton nuclear magnetic resonance spectroscopy was performed on a Varian GEMINI-300
spectrometer and spectra were taken in CDCl3 or D2O. The chemical shifts are expressed as
parts per million downfield from tetramethylsilane or as relative parts per million from HOD
peaks (4.78 ppm). 31P-NMR spectra were recorded at room temperature by use of Varian
XL-300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was used as an external
standard. High-resolution fast atom bombardment mass was performed with JEOL SX102
spectrometer using 6-kV Xe atoms. The phosphate and phosphonate derivatives were
desorbed from glycerol or magic bullet matrix.
All pyridoxal phosphate and phosphonate derivatives showed more than 95% purity in high
pressure liquid chromatography (HPLC) systems. The determinations of purity were
performed with a Hewlett-Packard 1090 HPLC system using an OD-5-60 C18 analytical
column (250 mm × 4.6 mm, Separation Methods Technologies, Inc., Newark, DE) in two
different linear gradient solvent systems. One solvent system (A) was 0.1 M
triethylammonium acetate buffer: CH3CN = 95:5 to 40:60 for 20 min with a flow rate of 1
ml/min. The other solvent system (B) was 5 mM tetrabutylammonium phosphate
buffer:CH3CN 80:20 to 40:60, in 20 min with a flow rate of 1 ml/min. Peaks were detected
by ultraviolet absorption with a diode array detector.
General Procedure of Azo Coupling for the Synthesis of PPADS Analogs
To a stirred solution of each aminoaryl compound (0.4 mmol) in 10 ml of water was added
0.4 ml (0.4 mmol) of 1 N HCl and 28 mg (0.4 mmol) of solid NaNO2 at 0°C. This solution
was stirred for 5 min and the pH was adjusted to ~10 with 1 N NaOH (about 0.2 ml). To the
mixture was added dropwise a solution of pyridoxal-5-phosphate (100 mg, 0.4 mmol) or a
phosphonate (0.4 mmol) previously dissolved in aqueous NaOH (pH ~10). The pH was
adjusted to ~9, and the yellow color changed to red. After stirring for 30 min at 0°C, the
progress of reaction was monitored by HPLC using solvent system A. The product peaks
appeared at retention times of 8–10 min with an ultraviolet absorption maximum at ~410
nm.
The mixture was frozen and lyophilized, leaving a solid. The crude product was dissolved in
a minimal volume of water and purified by ion-exchange column chromatography by using
Amberlite CG-50 resin (H+ form, weakly acidic) and eluting with water (flow rate 0.5 ml/
min). The red fraction showing a single peak in HPLC was collected and lyophilized to give
the desired compounds (yield, 50–60%).
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Starting with the intermediates 19, 22, 26, 28, and pyridoxal-α5-phosphate (1) and following
the general procedure, we have synthesized compounds 2, 4, 7–16, 20, 21, 23–25, 27, 29,
30, and 32–34 (Table 1).
6-Phenylazo-pyridoxal-α5-phosphate (sodium salt) (2)—1H NMR (D2O) δ 2.45
(3H, s, CH3), 5.67 (2H, d, J = 5.5 Hz, CH2), 7.49 (3H, m, aromatic H), 7.78 (2H, m,
aromatic-H), 10.33 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-3′-sulfonate (sodium salt) (4)—1H-NMR
(D2O) δ 2.53 (3H, s, CH3), 5.82 (2H, d, J = 5.9 Hz, CH2), 7.72 (1H, m, Ph), 7.96 (1H, d, J =
7.0 Hz, Ph), 8.12 (1H, d, J = 7.0 Hz, Ph), 8.31 (1H, s, Ph), 10.52 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-2′-methoxy-5′-sulfonate (sodium salt) (8)
—1H-NMR (D2O) δ 2.48 (3H, s, CH3), 4.09 (3H, s, OCH3), 5.81 (2H, d, J = 4.9 Hz, CH2),
7.37 (1H, d, J = 8.8 Hz, Ph), 7.94 (1H, d, J = 8.8 Hz, Ph), 8.14 (1H, s, Ph), 10.50 (1H, s,
CHO).
Pyridoxal-α5-phosphate-6-phenylazo-3′-carboxylic acid (sodium salt) (9)—1H-
NMR (D2O) δ 2.45 (3H, s, CH3), 5.73 (2H, d, J = 5.9 Hz, CH2), 7.63 (1H, t, J = 6.8 Hz, Ph),
8.03 (2H, m, Ph), 8.24 (1H, s, Ph), 10.45 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-4′-carboxylic acid (sodium salt) (10)—1H-
NMR (D2O) δ 2.51 (3H, s, CH3), 5.80 (2H, d, J = 5.9 Hz, CH2), 8.00 (4H, bs, Ph), 10.51
(1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-3′-chloro-2′-carboxylic acid (sodium salt)
(11)—1H-NMR (D2O) δ 2.57 (3H, s, CH3), 5.81 (2H, d, J = 6.8 Hz, CH2), 7.52 (1H, t, J =
7.8 Hz, Ph), 7.65 (1H, d, J = 7.8 Hz, Ph), 7.92 (1H, d, J = 7.8 Hz, Ph), 10.58 (1H, s, CHO).
6-(2′-chloro-phenylazo)-pyridoxal-α5-phosphate (sodium salt) (12)—1H-NMR
(D2O) δ 2.51 (3H, s, CH3), 5.74 (2H, d, J = 6.0 Hz, CH2), 7.43 (2H, m, Ph), 7.58 (1H, d, J =
7.8 Hz, Ph), 7.74 (1H, d, J = 7.8 Hz, Ph), 10.45 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-2′-chloro-5′-sulfonate (sodium salt) (13)
—1H-NMR (D2O) δ 2.48 (3H, s, CH3), 5.81 (2H, d, J = 5.7 Hz, CH2), 7.75 (1H, d, J = 7.8
Hz, Ph), 7.84 (1H, d, J = 7.8 Hz, Ph), 8.13 (1H, s, Ph), 10.49 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-2′-chloro-5′-carboxylic acid (sodium salt)
(14)—1H-NMR (D2O) δ 2.53 (3H, s, CH3), 5.83 (2H, d, J = 6.8 Hz, CH2), 7.70 (1H, d, J =
8.7 Hz, Ph), 7.99 (1H, d, J = 8.7 Hz, Ph), 8.18 (1H, s, Ph), 10.55 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-phenylazo-3′-chloro-4′-carboxylic acid (sodium salt)
(15)—1H-NMR (D2O) δ 2.49 (3H, s, CH3), 5.78 (2H, d, J = 5.9 Hz, CH2), 7.57 (1H, d, J =
7.8 Hz, Ph), 7.93 (1H, d, J = 7.8 Hz, Ph), 8.03 (1H, s, Ph), 10.50 (1H, s, CHO).
6-(2′-Chloro-5′-nitro-phenylzao)-pyridoxal-α5-phosphate (sodium salt) (16)
—1H-NMR (D2O) δ 2.54 (3H, s, CH3), 5.86 (2H, d, J = 6.0 Hz, CH2), 7.86 (1H, d, J = 7.8
Hz, Ph), 8.31 (1H, d, J = 7.8 Hz, Ph), 8.51 (1H, s, Ph), 10.58 (1H, s, CHO).
Dimethyl (3,α4-O-Isopropylidene-3-hydroxy-4-hydroxymethyl-2-methyl-pyrid-5-
yl)methylphosphonate (37)—To a solution of 5.11 g (0.0244 mol) of 35 in 100 ml of
benzene, was added 1.92 ml (0.0264 mol) of thionyl chloride. The mixture was refluxed for
Kim et al. Page 4













10 min with stirring and cooled to room temperature. The white solid was collected through
filtration, washed with anhydrous acetone, and dried under vacuum to afford 36 (6.1 g,
95%): mass spectrum (MS) (CI, NH3) 228(M++1), 245 (M+NH4+); 1H-NMR (CDCl3) δ
1.64 (6H, s, 2×CH3), 2.79 (3H, s, CH3), 4.65 (2H, s, CH2), 5.12 (2H, s, CH2), 8.31 (1H, s,
H6). The solution of 36 in 50 ml of trimethylphosphite was heated at 80°C for 48 h and
evaporated under vacuum. The residue was purified by flash silica gel column
chromatography with CHCl3:MeOH = 60:1 to afford 37 as a colorless oil (4.76 g, 61%): MS
(CI, NH3) 302(M+ + 1), 319(M+NH4+); high resolution mass spectroscopy (HRMS) (EI)
calcd. 301.1079, found 301.1064; 1H-NMR (CDCl3) δ 1.55 (6H, s, 2 × CH3), 2.39 (3H, s,
CH3), 3.00 (2H, d, J = 21.5 Hz, CH2), 3.68 (3H, s, CH3), 3.72 (3H, s, CH3), 4.93 (2H, s,
CH2), 7.92 (1H, s, H6).
Dimethyl (3-hydroxy-4-hydroxymethyl-2-methylpyrid-5-yl)methylphosphonate
(38)—A solution of 4.5 g (0.0149 mol) of 37 in 30 ml of 10% formic acid was refluxed for
2 h. After cooling, the mixture was partitioned between CHCl3 and saturated NaHCO3, and
the aqueous layer was extracted three times. The combined CHCl3 layer was dried over
anhydrous Na2SO4, evaporated, and purified by flash silica gel column chromatography
with CHCl3:MeOH = 20:1 to afford 38 as a white solid (2.62 g, 67%): mp = 139–141°C;
MS (CI, NH3) 262(M+ + 1); HRMS (EI) calcd. 261.0766, found 261.0752; 1H-NMR
(CDCl3) δ 2.48 (3H, s, CH3), 3.14 (2H, d, J = 20.5 Hz, CH2), 3.65 (3H, s, CH3), 3.69 (3H, s,
CH3), 4.86 (2H, s, CH2), 7.85 (1H, s, H6).
Dimethyl (4-formyl-3-hydroxy-2-methyl-pyrid-5-yl)methylphosphonate (39)—To
a solution of 1.05 g (4.02 mmol) of 38 in 80 ml of anhydrous CHCl3 was added powdered
activated MnO2 with vigorous stirring for 2 h at room temperature under N2 atmosphere.
The mixture was filtered through a Celite bed, and the filtrate was evaporated under vacuum
to afford 39 as a yellow oil (1.01 g, 97%): HRMS (EI) calcd. 259.0609, found 259.0594; 1H-
NMR (CDCl3) δ 2.52 (3H, s, CH3), 3.39, 3.46 (2H, 2s, CH2), 3.70 (3H, s, CH3), 3.74 (3H, s,
CH3), 8.00 (1H, s, H6), 10.37 (1H, s, CHO), 11.59 (1H, bs, OH).
4-Formyl-3-hydroxy-2-methyl-pyrid-5-yl)methylphosphonic acid (19)—To a
stirred solution of 0.8 g (3.09 mmol) of 39 in 30 ml of anhydrous CH3CN was added
dropwise 1.68 ml (12.3 mmol) of trimethylsilyl bromide. The mixture was stirred overnight
and evaporated under vacuum. The residue was mixed with 10 ml of water and followed by
dropwise addition of 6.5 ml of 0.5 M NH4HCO3 solution with stirring until the mixture
became a clear solution. The solution was washed with ether and applied to an Amberlite
CG-50 (H+ form) ion exchange column followed by elution with water. The pure fractions
determined by HPLC were collected and lyophilized to afford 19 as a yellow solid (0.55 g,
77%): mp = 310°C (dec.); 1H-NMR (D2O) δ 2.46 (3H, s, CH3), 3.36 (2H, d, J = 19.5 Hz,
CH2), 7.77 (1H, s, H6), 10.23 (1H, s, CHO); 31P-NMR (D2O) δ 17.12 (t, J = 19.4 Hz,
phosphonic acid).
5-Formyl-3,α4-O-isopropylidene-3-hydroxy-4-hydroxymethyl-2-methyl-pyridine
(40)—To a solution of 5.0 g (0.0239 mol) of 35 in 100 ml of anhydrous CH2Cl2 was added
powdered pyridinium dichromate (PDC) with vigorous stirring. After overnight stirring, the
mixture was filtered through a Celite bed. The filtrate was evaporated under vacuum and
purified by flash silica gel column chromatography with CHCl3:MeOH = 80:1 to afford 40
as a colorless oil (3.81 g, 77%): MS (CI, NH3) 208(M+ + 1), 225 (M+NH4+); 1H-NMR
(CDCl3) δ 1.57 (6H, s, 2 × CH3), 2.51 (3H, s, CH3), 5.18 (2H, s, CH2), 8.48 (1H, s, H6),
10.05 (1H, s, CHO).
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yl)propenoate (41)—To a suspension of 1.6 g (0.04 mol) of 60% sodium hydride
(prewashed twice with hexanes) in 200 ml of anhydrous tetrahydrofuran (THF) was added
dropwise 8.01 ml (0.04 mol) of triethylphosphonoacetate. The mixture became a clear
solution with evolution of H2 gas. After 5 min of stirring, 7.56 g (0.0364 mol) of 40 in 2 ml
of anhydrous THF was added and the solution stirred for 30 min. The mixture was
partitioned between CH2Cl2 and concentrated aqueous NaCl, and the organic layer dried
under anhydrous Na2SO4, and evaporated under vacuum. The product was crystallized from
hexanes to afford 41 as a white solid (9.65 g, 96%): mp = 81–83°C. Analysis: calcd. C
64.96, H 6.91, N 5.05; found C 65.06, H 6.94, N 5.01; MS (CI, NH3) 278(M+ + 1), 295(M
+NH4+); 1H-NMR (CDCl3) δ 1.34 (3H, t, J = 8.8 Hz, CH3), 1.57 (6H, s, 2 × CH3), 2.44 (3H,
s, CH3), 4.28 (2H, q, J = 8.8 Hz, CH2), 4.93 (2H, s, CH2), 6.37 (1H, d, J = 16.6 Hz, CH),
7.54 (1H, d, J = 16.6 Hz, CH), 8.27 (1H, s, H-6).
3-(3,α4-O-Isopropylidene-3-hydroxy-4-hydroxymethyl-2-methyl-pyrid-5-yl)-1-
propenol (42a)—To a stirred solution of 9.35 g (0.0337 mol) of 41 in 120 ml of anhydrous
THF was added 165 ml (0.165 mol) of 1.0 M diisobutyl aluminum hydride (DIBAL-H)
solution in THF at 0°C. The mixture was stirred for 2 h at 0°C, an additional 2 h at room
temperature, and quenched by 0.1 ml of MeOH. The mixture was poured into ice-cold 0.1 N
HCl, the pH was adjusted to 7–8, and the product was extracted with 100 ml of EtOAc three
times. The combined EtOAc layer was dried over anhydrous Na2SO4, evaporated under
vacuum, and purified by flash silica gel column chromatography with CHCl3:MeOH =
100:1 to afford 42a as a white solid (5.3 g, 67%): mp = 120–122°C; HRMS (EI) calcd.
235.1214, found 235.1208; 1H-NMR (CDCl3) δ 1.54 (6H, s, 2 × CH3), 2.39 (3H, s, CH3),
4.33 (2H, d, J = 4.9 Hz, CH2), 4.81 (2H, s, CH2), 6.27 (1H, dt, J = 4.9, 15.6 Hz, CH), 6.42
(1H, d, J = 15.6 Hz, CH), 8.07 (1H, s, H6).
3-(3,α4-O-Isopropylidene-3-hydroxy-4-hydroxymethyl-2-methyl-pyrid-5-yl)-1-
propenylchloride hydro-chloride salt (42b)—5.0 g (0.0212 mol) of 42a reacted by
using the same method as for 36 to afford 42b as a white solid (4.1 g, 67%): mp = 187°C
(dec.); HRMS (EI) calcd. 253.0870, found 253.0878; MS (CI, NH3) 254(M+ + 1), 271(M
+NH4+); 1H-NMR (CDCl3) δ 1.63 (6H, s, 2 × CH3), 2.78 (3H, s, CH3), 4.26 (2H, d, J = 4.9
Hz, CH2), 4.98 (2H, s, CH2), 6.46–6.58 (2H, m, 2 × CH), 8.247 (1H, s, H6).
Dimethyl 3-(3,α4-O-isopropylidene-3-hydroxy-4-hydroxymethyl-2-methyl-
pyrid-5-yl)-1-propenylphosphonate (42c)—0.14 g (0.482 mmol) of 42b reacted by
using the same method as for 37 except for the reaction temperature (120°C) to afford 42c as
a colorless oil (0.07 g, 45%): HRMS (EI) calcd. 327.1235, found 327.1241; 1H NMR
(CDCl3) δ 1.55 (6H, s, 2 × CH3), 2.39 (3H, s, CH3), 2.79 (2H, dd, J = 8.8, 22.5 Hz, CH2),
3.77 (3H, s, CH3), 3.81 (3H, s, CH3), 4.83 (2H, s, CH2), 6.02–6.12 (1H, m, CH), 6.36 (1H,
dd, J = 4.9, 15.6 Hz, CH), 8.10 (1H, s, H6).
Dimethyl 3-(3-hydroxy-4-hydroxymethyl-2-methyl-pyrid-5-yl)-1-
propenylphosphonate (43)—1.5 g (4.58 mmol) of 42b reacted by using the same
method as for 38 to afford 43 as a colorless oil (0.97 g, 74%): HRMS (EI) calcd. 287.0922,
found 287.0924; 1H-NMR (CDCl3) δ 2.39 (3H, s, CH3), 2.74 (2H, dd, J = 7.8, 22.5 Hz,
CH2), 3.73 (3H, s, CH3), 3.77 (3H, s, CH3), 4.95 (2H, s, CH2), 5.79–5.92 (1H, m, CH), 6.46
(1H, dd, J = 4.9, 15.6 Hz, CH), 7.83 (1H, s, H6).
3-(4-Formyl-3-hydroxy-2-methyl-pyrid-5-yl)-1-propenylphosphonic acid (31)—
0.2 g (0.696 mmol) of 43 reacted by using the same method as for 38 to 19 to afford 31 as a
yellow solid (0.12 g, two steps in 67%): mp = 118°C (dec.); 1H-NMR (D2O) δ 2.39 (3H, s,
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CH3), 2.62, 2.68 (2H, 2m, CH2), 6.14–6.27 (1H, m, CH), 6.58, 6.88 (1H, 2m, CH), 7.85
(1H, s, H6), 10.26 (1H, s, CHO); 31P-NMR (D2O) δ 20.15 (dq, J = 20.1, 4.9 Hz, phosphonic
acid).
Dimethyl 3-(3-hydroxy-4-hydroxymethyl-2-methyl-pyrid-5-yl)
propylphosphonate (44)—To a solution of 0.36 g (1.25 mmol) of 43 in CH2Cl2 was
added 0.36 g of Pd/C and stirred under H2 atmosphere (1 atm) at room temperature for 5 h.
The mixture was filtered through Celite bed. The filtrate was evaporated under vacuum and
purified by flash silica gel column chromatography with CHCl3:MeOH = 20:1 to afford 44
as a colorless oil (0.34 g, 93.8%): HRMS (EI) calcd. 289.1079, found 289.1073; 1H-NMR
(CDCl3) δ 1.77–1.87 (4H, m, 2 × CH2), 2.56 (3H, s, CH3), 2.71 (2H, t, J = 6.8, CH2), 3.73
(3H, s, OCH3), 3.76 (3H, s, OCH3), 5.03 (2H, s, CH2), 7.75 (1H, s, H6), 9.07 (2H, bs, 2 ×
OH).
3-(4-Formyl-3-hydroxy-2-methyl-pyrid-5-yl)-propylphosphonic acid (28)—0.23 g
(0.8 mmol) of 44 reacted by using the same method as for 38 to 19 to afford 28 as a yellow
solid (0.15 g, two steps in 72%): mp = 128°C (dec.); 1H-NMR (D2O + NaOD) δ 1.28–1.37
(2H, m, CH2), 1.58–1.83 (2H, m, CH2), 2.21, (3H, s, CH3), 2.61–2.83 (2H, m, CH2),
7.23(1H, s, H6), 10.28 (1H, s, CHO); 31P-NMR (D2O + NaOD) δ 22.65–23.01 (m,
phosphonic acid).
2-(4-Formyl-3-hydroxy-2-methyl-pyrid-5-yl)ethylphosphonic acid (22)—The title
compound was synthesized by the reported method [Hullar, 1969] with minor modification
of reagents. 1H-NMR (D2O + NaOD) d 1.47–1.58 (2H, m, CH2), 2.22, (3H, s, CH3), 2.75–
2.98 (2H, m, CH2), 7.29(1H, s, H6), 10.30 (1H, s, CHO); 31P-NMR (D2O + NaOD) d
21.41–21.71 (m, phosphonic acid).
2-(4-Formyl-3-hydroxy-2-methyl-pyrid-5-yl)-ethenylphosphonic acid (26)—The
title compound was synthesized by the reported method [Hullar, 1969] with minor
modification of reagents. 1H-NMR (D2O) δ 2.47 (3H, s, CH3), 6.41 (1H, dd, J = 17.6, 20.5
Hz, CH), 7.61 (1H, dd, J = 17.6, 20.5 Hz, CH), 7.89 (1H, s, H6), 10.39 (1H, s, CHO); 31P-
NMR (D2O) δ 10.77–11.08 (m, phosphonic acid).
[(4-Formyl-3-hydroxy-2-methyl-6-(2′,5′-disulfonylphenylazo))-pyrid-5-
yl]methylphosphonate (sodium salt) (20)—1H-NMR (D2O) δ 2.42 (3H, s, CH3),
3.98, 4.05 (2H, 2s, CH2), 7.82 (1H, d, J = 7.8 Hz, Ph), 8.04 (1H, d, J = 7.8 Hz, Ph), 8.16
(1H, s, Ph), 10.22 (1H, s, CHO).
[(4-Formyl-3-hydroxy-2-methyl-6-(2′-chloro-5′-sulfonylphenylazo))-pyrid-5-
yl]methylphosphonate (sodium salt) (21)—1H-NMR (D2O) δ 2.41, (3H, s, CH3),
3.92, 3.99 (2H, s, CH2), 7.63 (1H, d, J = 8.8 Hz, Ph), 7.73 (1H, d, J = 8.8 Hz, Ph), 8.03 (1H,
s, Ph), 10.25 (1H, s, CHO).
2-[(4-Formyl-3-hydroxy-2-methyl-6-(2′,5′-disulfonylphenylazo))-pyrid-5-
yl]ethylphosphonate (sodium salt) (23)—1H-NMR (D2O) δ 1.88–1.91 (2H, m, CH2),
2.40, (3H, s, CH3), 3.51–3.59 (2H, m, CH2), 7.76(1H, d, J = 7.8 Hz, Ph), 8.01 (1H, d, J = 7.8
Hz, Ph), 8.20 (1H, s, Ph), 10.25 (1H, s, CHO).
2-[(4-Formyl-3-hydroxy-2-methyl-6-(2′-chloro-5′-sulfonylphenylazo))-pyrid-5-
yl]ethylphosphonate (sodium salt) (24)—1H-NMR (D2O) δ 1.86–1.97 (2H, m, CH2),
2.40, (3H, s, CH3), 3.59–3.67 (2H, m, CH2), 7.63 (1H, d, J = 8.7 Hz, Ph), 7.74 (1H, d, J =
8.7 Hz, Ph), 8.00 (1H, s, Ph), 10.41 (1H, s, CHO).
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yl]ethylphosphonate (sodium salt) (25)—1H-NMR (D2O) δ 1.83–1.95 (2H, bm,
CH2), 2.42, (3H, s, CH3), 3.45–3.62 (2H, bm, CH2), 7.83 (4H, dd, J = 38.1, 6.8 Hz, Ph),
10.35 (1H, s, CHO).
2-[(4-Formyl-3-hydroxy-2-methyl-6-(2′,5′-disulfonylphenylazo))-pyrid-5-
yl]ethenylphosphonate (sodium salt) (27)—The title compound was purified by
crystallization from EtOH/H2O, due to the instability during the ion-exchange
chromatography. 1H-NMR (D2O) δ 2.35 (3H, s, CH3), 6.05 (1H, dd, J = 17.6, 19.5 Hz, CH),
7.78 (1H, dd, J = 17.6, 19.5 Hz, CH), 7.85 (1H, d, J = 8.7 Hz, Ph), 8.08 (1H, d, J = 8.7 Hz,
Ph), 8.31 (1H, s, Ph), 10.08 (1H, s, CHO).
3-[(4-Formyl-3-hydroxy-2-methyl-6-(2′,5′-disulfonylphenylazo))-pyrid-5-
yl]propylphosphonate (sodium salt) (29)—1H-NMR (D2O) δ 1.77–1.83 (4H, m, 2 ×
CH2), 2.41, (3H, s, CH3), 3.32–3.39 (2H, m, CH2), 7.75(1H, d, J = 7.8 Hz, Ph), 7.99 (1H, d,
J = 7.8 Hz, Ph), 8.16 (1H, s, Ph), 10.21 (1H, s, CHO).
3-[(4-Formyl-3-hydroxy-2-methyl-6-(2′-chloro-5′-disulfonylphenylazo))-pyrid-5-
yl]propylphosphonate (sodium salt) (30)—1H-NMR (D2O) δ 1.63–1.86 (4H, m, 2 ×
CH2), 2.42, (3H, s, CH3), 3.43–3.47 (2H, m, CH2), 7.62 (1H, d, J = 7.8 Hz, Ph), 7.74 (1H, d,
J = 7.8 Hz, Ph), 7.94 (1H, s, Ph), 10.37 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-(2′-naphthylazo-5′,7′-disulfonate) (sodium salt) (32)
—1H-NMR (D2O) δ 2.48, (3H, s, CH3), 5.74, (2H, bs, CH2), 8.29 (1H, d, J = 7.8 Hz, Naph),
8.41 (1H, s, Naph), 8.57 (2H, bs, Naph), 8.70 (1H, d J = 9.8 Hz, Naph), 10.39 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-(2′-naphthylazo-6′,8′-disulfonate) (sodium salt) (33)
—1H-NMR (D2O) δ 2.36, (3H, s, CH3), 5.71, (2H, d, J = 6.6, CH2), 7.97 (2H, pt, Naph),
8.35 (2H, pt, Naph), 9.05 (1H, bs, Naph), 10.39 (1H, s, CHO).
Pyridoxal-α5-phosphate-6-(2′-naphthylazo-3′,6′,8′-trisulfonate) (sodium salt)
(34)—1H-NMR (D2O) d 2.58, (3H, s, CH3), 5.87, (2H, d, J = 6.8 Hz, CH2), 8.53 (1H, s,
Naph), 8.70 (1H, s, Naph), 8.79 (2H, s, Naph), 10.57 (1H, s, CHO).
Pharmacology
Binding assay in differentiated HL-60 cell membranes—Human HL-60 cells were
obtained from American Type Culture Collection (Rockville, MD) and cultured in PRMI
1640 supplemented with 10% fetal bovine serum. To differentiate HL-60 cells, 1 × 106 cells/
ml were treated with phorbol myristate acetate (60 ng/ml) for 72 h. The differentiated cells
were washed twice with 10 ml of 10 mM Tris, 5 mM ethylenediaminetetraacetic acid buffer,
pH 8.25 at 5°C, and then scraped into 5 ml of the same buffer, The cells were homogenized,
the suspension was centrifuged at 35,000 × g for 20 min and the resulting pellet was
resuspended in 50 mM Tris buffer, pH 8.25 at 5°C, containing 1 mM
ethylenediaminetetraacetic acid. Membranes were frozen at −80°C before assay. The
binding of 0.2 nM [35S]ATPγS to HL-60 cell membranes was determined as described
[Buell et al., 1996] in a final assay volume of 0.25 ml. Incubations for 3 h at 4°C were
terminated by vacuum filtration. Non-specific binding was defined by using 10 μM ATPγS.
Antagonism of contractile responses of the guinea-pig urinary bladder and
vas deferens and relaxant responses of the guinea-pig taenia coli—Male white
guinea-pigs (250–400 g) were killed by a blow to the head and exsanguination. The urinary
bladder, vasa deferentia, and ventricular taenia coli were removed and strips of smooth
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muscle, approximately 2 × 10 mm, were prepared and suspended vertically in 10 ml organ
baths for isometric recording of mechanical activity. An initial load of 1 g was applied to the
strips which then were allowed to equilibrate for at least 60 min. Electrical field stimulation
(EFS) was applied by means of two platinum-wire rings 2.5 mm in diameter, 10 mm apart,
through which the strip was threaded. The modified Krebs solution used in these
experiments had the following composition (mM): NaCl 133, KCl 4.7, NaHCO3 16.4,
MgSO4 0.6, NaH2PO4 0.8, CaCl2 2.5 and glucose 7.7, gassed with 95% O2/5% CO2 (pH
7.3–7.4) and maintained at 37 ± 1°C. Contractions were recorded with a Linton FSG-01
force-displacement transducer, acquired by Biopac MP100WSW Data Acquisition System
and displayed on a PC screen. EFS was provided by a Grass S9 stimulator and applied at a
given frequency with a pulse width of 0.5 ms and supramaximal voltage. Adenosine-5′-
triphosphate disodium salt (ATP), phentolamine, atropine sulphate and carbamylcholine
chloride (carbachol) were obtained from Sigma (St. Louis, MO).
Atropine (0.3 μM) and phentolamine (1 μM) were present in a Krebs solution throughout
experiments on urinary bladder and vas deferens. Tissue was stimulated with EFS (0.5–64
Hz) until a maximal contraction was reached and the tone declined by approximately 30%.
Intervals of 1 min were maintained between stimulations. All contractile responses were
calculated as a percentage of the response evoked by KCl at a concentration of 240 mM,
which was added at the end of the experiment.
In experiments on taenia coli, relaxant responses to ATP (1, 10, and 100 μM) and to EFS
(0.5–8 Hz) were measured by using carbachol (25 nM) -precontracted tissue. Intervals of 10
min were maintained between two subsequent precontractions by carbachol for washout.
Relaxant responses were calculated as a percentage of maximal relaxation possible.
Responses to EFS and ATP were examined in preparations before and after incubation with
a given compound at a concentration of 10 and 30 μM for at least 30 min. Time-control
preparations were maintained in parallel and established that there was no significant change
in response to EFS or ATP throughout experiments.
Each concentration of compound was tested three times on tissues from three different
animals (n = 3). Means were compared by the paired Student's t-test. A probability of =0.05
was considered as significant. Data are presented as mean (M) ± s.e.m.
Antagonist activity at recombinant P2X2 receptors—Xenopus oocytes were
harvested and prepared as previously described [King et al., 1997]. Defolliculated oocytes
were injected cytosolically with rat P2X2 cRNA (30 nL, 1 μg/ml) [Brake et al., 1994]
incubated for 24 h at 18°C in Barth's solution and kept for up to 12 days at 4°C until used in
electrophysiologic experiments.
ATP-activated membrane currents (Vh = −90 mV) were recorded from cRNA-injected
oocytes by using the twin-electrode voltage-clamp technique (Axoclamp 2B amplifier).
Voltage recording (1–2 MΩ tip resistance) and current-recording microelectrodes (5 MΩ tip
resistance) were filled with 0.6 M K2SO4 and 3.0 M KCl, respectively. Oocytes were held in
an electrophysiologic chamber and superfused with Ringer's solution (5 mM/min, at 18°C)
containing (mM) NaCl, 110; KCl, 2.5; HEPES, 5; CaCl2, 1.8, adjusted to pH 7.5.
ATP (10 μM, approximately the EC70 value) was superfused over the oocytes for 120 s then
washed out for a period of 5 min. For inhibition curves, data were normalized to the current
evoked by ATP at pH 7.5. Test substances were added for 5 min before ATP exposure; all
compounds were tested for reversibility of their effects. The concentration required to inhibit
the ATP response by 50% (IC50) was taken from Hill plots constructed by using the formula
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log(I/Imax - 1), where I is the current evoked by ATP in the presence of an antagonist. Data
are presented as mean ± s.e.m. (n = 4) for data from different batches of oocytes.
Phospholipase C assay—P2Y1 receptor-promoted stimulation of inositol phosphate
formation by adenine nucleotide analogs was measured in turkey erythrocyte membranes as
previously described [Harden et al., 1988; Boyer et al., 1989]. The K0.5 values were
averaged from three to eight independently determined concentration-effect curves for each
compound. Briefly, 1 ml of washed turkey erythrocytes was incubated in inositol-free
medium (DMEM; Gibco, Gaithersburg, MD) with 0.5 mCi of 2-[3H]myo-inositol (20 Ci/
mmol; American Radiolabeled Chemicals, Inc., St. Louis, MO) for 18–24 h in a humidified
atmosphere of 95% air 5% CO2 at 37°C. Erythrocyte ghosts were prepared by rapid lysis in
hypotonic buffer (5 mM sodium phosphate, pH 7.4, 5 mM MgCl2, 1 mM EGTA) as
previously described [Boyer et al., 1989]. Phospholipase C activity was measured in 25 μl
of [3H]inositol-labeled ghosts (~175 μg of protein, 200–500,000 cpm/assay) in a medium
containing 424 μM CaCl2, 0.91 mM MgSO4, 2 mM EGTA, 115 mM KCl, 5 mM KH2PO4,
and 10 mM HEPES, pH 7.0. Assays (200-μl final volume) contained 1 μM GTPγS and the
indicated concentrations of nucleotide analogs. Ghosts were incubated at 30°C for 5 min,
and total [3H]inositol phosphates were quantitated by anion exchange chromatography as
previously described [Harden et al., 1988; Boyer et al., 1989].
Agonist potencies were calculated by using a four-parameter logistic equation and the
GraphPad software package (GraphPad, San Diego, CA). Antagonist IC50 values (mean ±
standard error) represent the concentration needed to inhibit by 50% the effect elicited by 10
nM 2-methylthioadenosine-5′-diphosphate. All concentration-effect curves were repeated in
at least three separate experiments carried out with different membrane preparations by
using duplicate or triplicate assays.
RESULTS
Synthesis
The 6-arylazopyridoxal-5-phosphate analogs that were prepared and characterized (Table 1)
could be divided into three categories. Among substituted-phenylazo derivatives and their
precursors (Table 2) there are both 5-phosphate (compounds 1–18) and 5-phosphonate
(compounds 19–31) analogs, and several naphthylazo pyridoxal-5-phosphate derivatives
(compounds 32–34) have been included. The phosphate analogs were modified through
substitution of the phenyl ring with sulfo, chloro, nitro, and carboxylate groups. The
phosphonate analogs all contain 5′-sulfo and either chloro- or sulfo-groups at the 2′-
position. Several compounds (compounds 1–3, 5, 6, 17, and 18) previously reported by
Lambrecht [1996] are included in this study for comparison.
The synthetic procedures for the various 3-hydroxy-2-methyl-pyridine-5-alkyl or 5-olefinic
phosphonic acid derivatives are shown in Scheme 1. The starting isopropylidene derivative,
35, was synthesized from pyridoxine according to the previous report [Yang et al., 1991].
The transformation of hydroxymethyl group of 35 to the corresponding chloromethyl group
of 36 [Tomita et al., 1966], followed by an Arbuzov reaction using trimethylphosphite,
afforded the phosphonate compound, 37 with an overall yield of 61%. After the hydrolytic
cleavage of isopropylidene group of 37 with 10% formic acid, oxidation of 4-hydroxymethyl
group of 38 with activated manganese (IV) oxide provided the 4-formyl compound 39 in
high yield. A mild deprotection of the dimethyl ester of the phosphonate was accomplished
by an ester exchange reaction by using trimethylsilyl bromide and followed by hydrolysis of
the silyl esters. After purification, by using ion exchange chromatography (Amberlite
CG-50, H+ form), 19 was isolated in moderate yield.
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The precursor for chain extension between the pyridine ring and the phosphonic acid group
was compound 40, which was obtained by oxidation of 35 by using PDC in CH2Cl2. 5-
trans-Vinyl and 5-ethyl phosphonate derivatives, 26 and 22, were synthesized by the
reported procedures [Hullar, 1969] with minor modification of reagents. 5-Allyl and 5-
propyl phosphonic acid derivatives were prepared through a Wittig reaction of the aldehyde
group [Tomita et al., 1966] in 40 leading to the trans-vinyl carboxylic acid ester, 41.
Selective reduction of the ester in 41 with DIBAL-H afforded the alcohol 42a, which was
converted to phosphonate 31 by using the same procedures as for the preparation of 19 from
35. A saturated propyl phosphonate, 28, was prepared through catalytic reduction of the
dimethyl phosphonate intermediate, 43, followed by oxidation and deprotection.
The phosphonic acid derivatives, 19, 22, 26, and 28 were subjected to the azo coupling
reaction (Scheme 2) with two different aromatic amine moieties, aniline-2,5-disulfonic acid
and aniline-2-chloro-5-sulfonic acid. The azo-linked products obtained were compounds 20,
21, 23–25, 27, 29, and 30 (Table 2). The chemical characterization and HPLC retention
times in two solvent systems of these compounds are reported in Table 1.
Radioligand Binding Studies at Human P2X1 Receptors
Assays at P2X receptors consisted of both radioligand binding and biological assays. The
binding assay involved inhibition of specific binding of [35S]ATP-γ-S to membranes of
HL-60 cells. The P2X1 receptor is the principal subtype of P2 receptors expressed in
differentiated HL-60 cells, and agonist binding selectivities determined with HL-60
membranes were shown by Buell et al. [1996] to correspond to the affinity of agonists at the
human P2X1 receptor. We verified that the order of potency in inhibition of radioligand
binding by known receptor agonists and antagonists was approximately as expected from the
published potencies at P2X1 receptors. For example, the following IC50 values (all nM)
were measured: ATP, 5.51 ± 0.37; ATP-γ-S, 3.88 ± 1.14; 2-Cl-ATP, 6.55 ± 1.60; L-β,γ-
me-ATP; 24,800 ± 5400; suramin, 730 ± 171.
The IC50 values for most of the PPADS derivatives in the P2X1 receptor binding assay were
greater than 100 μM (Table 3). Even PPADS, 6, displayed only 18% inhibition at 100 μM,
which was somewhat weaker than expected. IsoPPADS, 7, was somewhat more potent than
PPADS in inhibition of binding. Several derivatives displayed relatively favorable affinity in
the binding assay. For example, a phenylazo phosphonate derivative, 27, and a naphthylazo
phosphate derivative, 32, exhibited IC50 values of 10 and 15 μM, respectively. Both of these
compounds contained two sulfonate groups on the aryl rings. Compound 2, an unsubstituted
phenylazo phosphate derivative, was of intermediate affinity with an IC50 value of 45 μM.
Smooth Muscle Assays at Guinea-pig P2X1 Receptors—Functional assays
consisted of classic smooth muscle systems, specifically antagonism of electric field-
stimulated contraction (P2X system) of vas deferens and guinea-pig urinary bladder. Most of
the phosphate and a few phosphonate derivatives displayed antagonism to some degree in
the smooth muscle assays of guinea-pig P2X1 receptors in the urinary bladder [Ziganshin et
al., 1993] and vas deferens [McLaren et al., 1994]. The three most potent analogs in the
human P2X1 receptor binding assay, i.e., 2, 27, and 32, showed considerable potency of
varying degrees in these smooth muscle assays. The compounds that consistently showed
the greatest degree of antagonism in both bladder and vas deferens were: 8, 10, 13, 20, and
34. Curiously, compounds 12, 16, 21, and 28–30 antagonized electric field-induced
contraction in the vas deferens but not in the bladder. Compound 10, a phosphate derivative
that contained a carboxyl group at the 4-position of the phenylazo ring, displayed a
particularly favorable degree of antagonism in both bladder (Fig. 2A) and vas deferens (Fig.
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2B). The m-chloro-p-carboxyphenylazo derivative 15 inhibited contraction in the bladder,
whereas in the vas deferens inhibition occurred at = 16 Hz but not at 8 Hz stimulation.
Smooth Muscle Assay at Guinea-pig P2Y1 Receptors and Biochemical Assay at Turkey
Erythrocyte P2Y1 Receptors
Antagonism at P2Y1 receptors was established by using a smooth muscle system, i.e.
guinea-pig taenia coli, in which antagonism of either agonist-induced or electric field–
induced relaxation was measured [Windscheif et al., 1995a]. The phenylazo derivative
phosphate derivative 2 and the ethylphosphonate analog of isoPPADS 23 had measurable
KB values in antagonizing ATP-induced relaxation of 6.3 and 12.5 μM, respectively. Other
compounds that consistently showed the greatest degree of antagonism in the guinea-pig
taenia coli were 8, 9, 11, 19, 29, and 34. The ethyl phosphonate derivative 25 was essentially
inactive at guinea-pig P2Y1 receptors and was also inactive as an antagonist at P2Y receptors
of C6 glioma cells (data not shown) [Boyer et al., 1994]. The compounds were further
evaluated at the phospholipase C-coupled P2Y1 receptor of turkey erythrocytes. At both
guinea-pig and turkey erythrocyte P2Y1 receptors, most of the phosphate derivatives, except
for compounds 10 and 15, showed activity similar to PPADS, 6. Compounds 10 and 15 were
either inactive or very weak at both taenia coli (Fig. 3) and turkey erythrocyte P2Y1
receptors. Potency of antagonism at turkey erythrocyte P2Y1 receptors among compounds
with IC50 values of <10 μM decreased in the order 12, 21, 14, 34>8, 13, 24, 16, 33, 32, 6.
Phosphonate derivatives, except for compounds 21 and 24, were inactive or very weak at
turkey erythrocyte P2Y1 receptors. Compound 21, although relatively potent at turkey
erythrocyte P2Y1 receptors (IC50 value of 7.23 μM), was inactive in the guinea-pig taenia
coli. Among the phosphonate congeners, the homologous 2-chloro-5-sulfonyl-phenylazo
phosphonate derivatives 21, 24, and 30 displayed a trend of decreasing potency at turkey
erythrocyte P2Y1 receptors, depending on the chain length between the pyridine ring and
phosphorous atom (Table 3). Nevertheless, a measurable potency (IC50 value of 20.2 μM)
was observed even for the propyl phosphonate 30.
Curiously, the propyl phosphonate derivative 30 and the naphthylazo derivative 33 seemed
to enhance the relaxation of the taenia coli in response to ATP but not to electrical
stimulation. This phenomenon may conceivably occur through potential inhibition of
enzymes which degrade ATP, such as nucleotidases, by the analogs. Numerous derivatives
that act as ATP antagonists are also known to inhibit ecto-nucleotidases [Jacobson et al.,
1997].
Although pyridoxal-5-phosphate 1 itself has P2-antagonist properties [Trezise et al., 1994],
the presence of the 6-arylazo moiety (with or without substitution) clearly enhanced potency
at P2 receptors. The other non–azo-linked pyridoxal-5-phosphate/phosphonate precursors
19, 22, 26, and 28 were all essentially inactive at turkey erythrocyte P2Y1 receptors.
Recombinant Rat P2X2 Receptor Ion Channel Assay—Compounds were tested in a
functional assay of recombinant rat P2X2 receptors expressed in Xenopus oocytes, in which
ATP-induced currents were inhibited (Fig. 4) [King et al., 1997]. Of the novel compounds
synthesized in our study, compound 15 was the most potent at rat P2X2 receptors, with an
IC50 value of 0.82 μM. Thus, 15 was intermediate in potency between isoPPADS, 7, and
PPADS, 6, which had IC50 values of 0.40 and 1.6 μM, respectively. Other compounds that
displayed roughly the same potency as PPADS at rat P2X2 receptors were the unsubstituted
phenylazo derivative 2, the m-carboxyphenylazo derivative 9, the methylphosphonate
analog of isoPPADS 20, and the corresponding ethylphosphonate 23, and the p-
carboxyphenylazo ethylphosphonate derivative 25. The order of potency at rat P2X2
receptors evident in Figure 4 was 7 > 15 > 20, 2 > 23, 6 > 25, 9. Thus, the particular
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combination of phosphonate and substituted phenylazo units has indications of displaying
relatively high potency at the P2X2 receptor subtype.
PPADS has been shown to inhibit P2X receptors with slow reversibility [Windscheif et al.,
1995a; Humphrey et al., 1995]. The effects of some derivatives (2, 7, 15, 20, 23, and 25) at
the rat P2X2 receptor were readily reversible, whereas others (6, 9, 10, 22, and 29) were only
slowly reversible (data not shown).
DISCUSSION
In contrast to the initial reports, it seems that PPADS is not selective for P2X receptors. As
reconfirmed in this study, PPADS also has considerable affinity for P2Y receptors
[Schachter et al., 1996; Boyer et al., 1994; Brown et al., 1995]. In the present study, PPADS
and isoPPADS and numerous analogs thereof, were compared in a variety of P2X and P2Y
receptor assays. We have shown that at rat P2X2 and turkey erythrocyte P2Y1 receptors,
isoPPADS is more potent as an antagonist than PPADS. Recently we have shown that
isoPPADS is more potent than PPADS also at recombinant rat P2X1 receptors [Jacobson et
al., 1998]. Thus, the 2′,5′-disulfonate substitution of the phenylazo ring is a more favorable
lead structure for ligand development than the 2′,4′-isomer.
In the present study, we have greatly expanded the range of PPADS and isoPPADS analogs
for the study of SARs and selectivity at various P2 receptor subtypes. Based on mutagenesis
results, the 4-aldehyde moiety of PPADS is proposed to aid in binding of the antagonist
through the formation of a Schiff base with the ε-amino group of a specific lysine residue on
the large extracellular domain of P2X1 and P2X2 receptors [Humphrey et al., 1995]. All of
the present analogs have retained the aldehyde group. The potency of PPADS as a P2X
antagonist has been reported to be not highly dependent on substituents in the 6-phenylazo
ring, except for electron-withdrawing substituents, such as a nitro group, which decreases
the potency [Lambrecht et al., 1996]. We have confirmed that the unsubstituted phenylazo
derivative 2 acts as a P2 receptor antagonist and found further substitution patterns on the
arylazo ring that serve to modulate the potency and selectivity of the derivatives.
A major finding of the present study is that the phosphate group of PPADS may be replaced
with a phosphonate resulting in preservation of P2 receptor antagonist properties. The 5-
methylphosphate group of PPADS was previously shown to be required for its activity as a
P2 receptor antagonist [Trezise et al., 1994], and the present study reveals that a
phosphonate substitution is also acceptable for P2 receptor antagonism. The phosphonate
group may be linked to the pyridine ring at the 5-position through a hydrocarbon chain
consisting of methyl, ethyl, propyl, vinyl or allyl groups. Among the these analogs, the
saturated chain-linked phosphonate compound 23 showed significant selectivities for P2X2
receptors vs. P2X1 or P2Y1 receptors, whereas in the case of vinyl phosphonate analogs the
potency at P2X1 receptors was restored. These results indicate that altering the electron
density or electrostatic potential surrounding the phosphate group in PPADS may be a
means of resolving selectivity among the subtypes.
Compounds 10 and 15, both of which contained a carboxyl group at the 4-position of the
phenylazo ring, displayed particularly good selectivity for P2X compared with P2Y1
receptors (Figs. 2, 3). Of the novel compounds synthesized in our study, compound 15, a 3′-
chloro-4′-carboxylic acid derivative, was the most potent at P2X2 receptors. Compound 15
was essentially inactive at guinea-pig and turkey P2Y1 receptors and at 30 μM only
moderately antagonized guinea-pig bladder P2X1 receptors (see below). Thus, compound 15
is of further interest as a selective pharmacologic probe of P2X2 receptors. Compound 10, a
4′-carboxylic acid derivative, and compound 20, a methylphosphonate derivative, were not
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very selective within P2X subtypes examined but were highly selective when compared with
P2Y1 receptors. Also, compounds 23 and 25 were relatively potent at rat P2X2 receptors,
whereas 23 was relatively weak at both P2X1 and P2Y1 receptors (Table 3). Considerable
differences between the taenia coli and turkey P2Y receptors in antagonist potency were
evident (Table 3), suggesting the presence of different subtypes. Similarly among agonists,
α,β-me-ATP is active in the taenia coli [Burnstock et al, 1994] but not at recombinant P2Y1
receptors.
The development of potent and selective antagonists of P2 receptors remains a challenge.
Among nucleotide antagonists, a P2Y1 selective antagonist N6-methyl-2′-
deoxyadenosine-3′,5′-bisphosphate (MRS 2179) having a Ki value of approximately 100
nM was recently reported [Camaioni et al., 1998; Boyer et al., 1998]. Non-nucleotide
heterocyclic P2 receptor antagonists (PPADS, Reactive Blue 2, suramin, etc.) have not
shown subtype selectivity before the present study [Jacobson et al., 1997]. In the present
study, we have identified several novel derivatives of PPADS, that display encouraging
selectivity, including the p-carboxyphenylazo phosphate derivative 10 (MRS 2159) and its
m-chloro analog 15 (MRS 2160), which were selective for P2X vs. P2Y1 receptors. Among
the phosphonate derivatives, [4-formyl-3-hydroxy-2-methyl-6-(2-chloro-5-
sulfonylphenylazo)-pyrid-5-yl]methylphosphonic acid, 21 (MRS 2192), showed high
potency at P2Y1 receptors with an IC50 of 7.23 μM. The corresponding 2,5-
disulfonylphenyl derivative 20 (MRS 2191) was nearly inactive at turkey erythrocyte P2Y1
receptors, whereas at recombinant P2X2 receptors had an IC50 value of 1.1 μM. Thus a
single ring substitution, sulfo instead of chloro, has a major effect on the selectivity of these
methylphosphonates as P2Y receptor antagonists. An ethyl phosphonate derivative 23 (MRS
2142) was selective for recombinant P2X2 vs. either P2X1 or turkey erythrocyte P2Y1
receptors.
The present study demonstrates that it is possible to achieve selectivity for P2 receptor
subtypes by using a relatively nonselective lead structure, PPADS. It will be necessary to
study the present set of PPADS analogs at other P2 receptor subtypes and compare potencies
within the same species to establish the complete pharmacologic profiles as antagonists.
PPADS itself does not potently antagonize P2Y2, P2Y4, or P2Y6 receptors. Also, at P2X
receptors, PPADS is much more potent at P2X1–P2X3 and P2X5 receptors than at P2X4,
P2X6, and P2X7 receptors. Thus, by optimizing the pharmacologic properties of PPADS
analogs, it may be possible to achieve high affinity and selectivity for subtypes within P2X
and P2Y receptor families.
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Structure of pyridoxal-6-phenylazo-5′-phosphate or phosphonate derivatives prepared in the
present study.
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P2X1 receptor-mediated contractile responses of control (white bars) and compound 10 (10
μM, slash bars; 30 μM, black bars) calculated as percentage of the response evoked by KCl
at a concentration of 240 mM, which was added at the end of experiments. (A) Guinea-pig
urinary bladder and (B) guinea-pig vas deferens were stimulated with electrical field
stimulation (0.5–64 Hz) in a Krebs solution containing atropine (0.3 μM) and phentolamine
(1 μM) until a maximal contraction was reached and the tone declined by approximately a
third. Intervals of 1 min were always kept between two subsequent stimulations. *, P < 0.05
from control; ^, P < 0.05 from 10 μM (n = 3).
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P2Y1 receptor-mediated relaxant responses of control (white bars) and compound 10 (10
μM, slash bars; 30 μM, black bars) calculated as a percentage of maximal relaxation
possible: guinea-pig taenia coli relaxant responses to ATP (1, 10, and 100 μM) and to
electrical field stimulation (0.5–8 Hz) were tested on carbachol-precontracted tissue (25
nM). Intervals of 10 min were kept between two subsequent precontractions by carbachol
for washout.
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Effects of various analogs as indicated on current induced by activation by 10 μM ATP
(approximate EC70 value) of recombinant rat P2X2 receptors, expressed in Xenopus
oocytes, by using the twin-electrode voltage-clamping technique. The medium consisted of
Ca2+ Ringer's buffer at pH 7.50.
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a: SOCl2 in benzene, reflux, 10 min. b: P(OCH3)3, reflux, 48 h. c: 10% formic acid reflux, 2
h. d: Activated MnO2 in CHCl3, 2 h. e: TMS-Br in CH3CN, 24 h. f: PDC in CH2Cl2, 24 h.
g: EtOCOCH2P(O)(OEt)2, NaH in THF, 30 min. h: DIBAL-H in THF at 0°C, 2 h. i: 1
atmosphere H2, Pd/C in CH2Cl2, 5 h.
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Ar, substituted phenyl or naphthyl. The precise structures are presented in Table 2.
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